UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
4mNpr6
4mNpr6
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Presentations<br />
Off-target resistance to inhibitors of BCR-ABL and FLT3 in<br />
myeloid malignancies<br />
Authors*: Neil P. Shah<br />
Pres #: Section: Presentation Date/Time: Monday, April 18: 2:00-2:25PM<br />
Location: Room 265<br />
Presentation Type: Recent Advances in Organ Site Research<br />
Shah Lab Expertise : The Shah lab is interested in advancing targeted therapeutics for hematologic<br />
malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding<br />
critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained<br />
from patients participating in early phase monotherapy clinical studies to identify, validate and override<br />
mechanisms of resistance to these agents.<br />
https://shah.ucsf.edu/<br />
__________________________________________________________________________<br />
Translation of hyperpolarized 13 C imaging to the clinic<br />
Authors*: John Kurhanewicz<br />
Pres #: Section: Presentation Date/Time: Monday, April 18: 2:10-2:35PM<br />
Location: Room 260 Presentation Type: Major Symposium<br />
Kurhanewicz Lab Expertise<br />
__________________________________________________________________________<br />
Targeting adaptive pathways in metastatic treatment resistant<br />
prostate cancer<br />
Authors*: Eric Small<br />
Pres #: Section: Presentation Date/Time: Monday, April 18: 3:28-3:51PM<br />
Location: Room 243<br />
Presentation Type: Special Session<br />
Small Lab Expertise: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea<br />
that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular<br />
responses — what the Dream Team calls “adaptive pathways” — to escape the current prostate cancer<br />
therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome<br />
treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six<br />
institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia,<br />
Oregon Health and Science University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
*<strong>UCSF</strong> authors in bold<br />
28
Change language